M1 Kliniken AG

XTER:M12 (Germany)  
€ 13.55 (-2.52%) Apr 22
43.44
P/B:
2.59
Market Cap:
€ 248.17M ($ 264.91M)
Enterprise V:
€ 212.26M ($ 226.58M)
Volume:
9.82K
Avg Vol (2M):
20.37K
Warning! GuruFocus detected 2 Severe warning signs with M12. Try a 7-Day Free Trial to check it out.
Also Trade In:
Volume:
9.82K
Market Cap €:
248.17M
Market Cap $:
264.91M
43.44
Avg Vol (2M):
20.37K
Enterprise Value €:
212.26M
Enterprise Value $:
226.58M
PB Ratio:
2.59
Alerts Website Sources Stock PDF
Dataset
Financial Download Manual of Stocksâ„¢

Business Description

M1 Kliniken AG

ISIN : DE000A0STSQ8
https://www.m1-kliniken.de
Grunauer strasse 5, Berlin, BB, DEU, 12557
Compare
Compare
XTER:MEDXTER:MAKXTER:V3VFRA:EIFXTER:RHKHCASZSE:300015SAU:4013HKSE:06618XTER:FREBKK:BDMSXKLS:5225BSP:RDOR3XTER:FMEUHSCHENSE:APOLLOHOSPAGLASX:RHCDVA
Traded in other countries / regions
M12.GermanyMKLNF.USA
IPO Date
2015-09-14
Description
M1 Kliniken AG is a healthcare company operating in the market for aesthetic medical treatment and plastic surgery. It operates through Beauty and Trade segments. Its activities are focused on providing aesthetic medical treatment. In addition to medical aesthetic treatments, the company also develops and markets pharmaceutical, medical and medical technology products for aesthetic surgery and cosmetic dermatology. Some of the treatments offered by the group are lip under injection, eyebrow lift, tummy tuck, breast reduction, sweat treatment, liposuction, and others. The organization conducts its business operations in Germany. Majority of its revenue derived from Trade segment.

Financial Strength

9/10
Name Current Vs Industry Vs History
Cash-To-Debt 3.74
Equity-to-Asset 0.48
Debt-to-Equity 0.13
Debt-to-EBITDA 0.66
Interest Coverage 11.87
Piotroski F-Score 6/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 5.16
Distress
Grey
Safe
Beneish M-Score -2.69
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

6/10
Name Current Vs Industry Vs History
3-Year Revenue Growth Rate 48.8
3-Year EBITDA Growth Rate -2.5
3-Year EPS without NRI Growth Rate -22
3-Year Book Growth Rate 9.5

Momentum Rank

6/10
Name Current Vs Industry Vs History
5-Day RSI 41.74
9-Day RSI 48.77
14-Day RSI 51.22
6-1 Month Momentum % 55.44
12-1 Month Momentum % 66.46

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 2.73
Quick Ratio 2.1
Cash Ratio 1.16
Days Inventory 39.03
Days Sales Outstanding 31.86
Days Payable 28.44

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -1.5
Shareholder Yield % -0.54

Profitability Rank

8/10
Name Current Vs Industry Vs History
Gross Margin % 16.95
Operating Margin % 3.95
Net Margin % 2.14
FCF Margin % 3.86
ROE % 6.62
ROA % 3.23
ROIC % 6.14
ROC (Joel Greenblatt) % 36.39
ROCE % 8.92
Years of Profitability over Past 10-Year 9

GF Value Rank

7/10
Name Current Vs Industry Vs History
PE Ratio 43.44
PE Ratio without NRI 53.46
Price-to-Owner-Earnings 14.1
PEG Ratio 3.79
PS Ratio 0.93
PB Ratio 2.59
Price-to-Tangible-Book 6.55
Price-to-Free-Cash-Flow 23.8
Price-to-Operating-Cash-Flow 21.12
EV-to-EBIT 14.98
EV-to-EBITDA 10.6
EV-to-Revenue 0.72
EV-to-FCF 19.05
Price-to-Projected-FCF 1.65
Price-to-Peter-Lynch-Fair-Value 4.91
Price-to-Graham-Number 3.89
Price-to-Net-Current-Asset-Value 24.2
Earnings Yield (Greenblatt) % 6.68
FCF Yield % 4.63
Forward Rate of Return (Yacktman) % 16.11

Financials

XTER:M12's 30-Y Financials
AAPL
Income Statement Breakdown
No Enough Data
AAPL
Balance Sheet Breakdown
No Enough Data
AAPL
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

M1 Kliniken AG Executives

Details

GF Value: €14.99

XTER:M12

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €) 297.416
EPS (TTM) (€) 0.32
Beta 1.03
Volatility % 41.76
14-Day RSI 51.22
14-Day ATR (€) 0.558145
20-Day SMA (€) 13.4725
12-1 Month Momentum % 66.46
52-Week Range (€) 7.28 - 14.95
Shares Outstanding (Mil) 18.32

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 6
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

M1 Kliniken AG Filings

Filing Date Document Date Form
No Filing Data

M1 Kliniken AG Stock Events

Financials Calendars
Event Date Price(€)
No Event Data

M1 Kliniken AG Frequently Asked Questions

What is M1 Kliniken AG(XTER:M12)'s stock price today?
The current price of XTER:M12 is €13.55. The 52 week high of XTER:M12 is €14.95 and 52 week low is €7.28.
When is next earnings date of M1 Kliniken AG(XTER:M12)?
The next earnings date of M1 Kliniken AG(XTER:M12) is .
Does M1 Kliniken AG(XTER:M12) pay dividends? If so, how much?
M1 Kliniken AG(XTER:M12) does not pay dividend.

Press Release

Subject Date
No Press Release
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2024 GuruFocus.com, LLC. All Rights Reserved.